EA201170182A1 - Композиции эпросартана - Google Patents

Композиции эпросартана

Info

Publication number
EA201170182A1
EA201170182A1 EA201170182A EA201170182A EA201170182A1 EA 201170182 A1 EA201170182 A1 EA 201170182A1 EA 201170182 A EA201170182 A EA 201170182A EA 201170182 A EA201170182 A EA 201170182A EA 201170182 A1 EA201170182 A1 EA 201170182A1
Authority
EA
Eurasian Patent Office
Prior art keywords
eprosartan
dose
administered
compound
compositions
Prior art date
Application number
EA201170182A
Other languages
English (en)
Inventor
Паулюс А.Й. Линк
Марселлус М. Ван Дер Хюлст
Герхард-Вильхельм Биленберг
Корнелис Р. Ван Ден Аккер
Original Assignee
Эбботт Хелткэа Продактс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Хелткэа Продактс Б.В. filed Critical Эбботт Хелткэа Продактс Б.В.
Publication of EA201170182A1 publication Critical patent/EA201170182A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описанное изобретение относится к способу лечения расстройства, модулируемого блокированием рецепторов ангиотензина II (AII), в частности, выбранного из группы, состоящей из гипертензии, застойной сердечной недостаточности, почечной недостаточности и их комбинации, введением нуждающемуся в нем субъекту эффективной дозы соединения эпросартана. С учетом рекомендуемой эффективной суточной дозы 600 мг, рассчитанной на основании эпросартана, вводимого в форме эпросартана мезилата, в настоящее время было обнаружено, что может вводиться более низкая доза эпросартана, когда соединение эпросартана представляет собой эпросартановую кислоту. Эта доза находится в диапазоне от 410 до 490 мг, наиболее предпочтительно примерно 450 мг.
EA201170182A 2008-07-11 2009-07-09 Композиции эпросартана EA201170182A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8006708P 2008-07-11 2008-07-11
EP08160211 2008-07-11
PCT/EP2009/058724 WO2010003996A1 (en) 2008-07-11 2009-07-09 Eprosartan compositions

Publications (1)

Publication Number Publication Date
EA201170182A1 true EA201170182A1 (ru) 2011-08-30

Family

ID=39731507

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170182A EA201170182A1 (ru) 2008-07-11 2009-07-09 Композиции эпросартана

Country Status (21)

Country Link
US (2) US20100010062A1 (ru)
EP (1) EP2317987B1 (ru)
JP (1) JP2011527314A (ru)
KR (1) KR20110031226A (ru)
CN (1) CN102088961A (ru)
AR (1) AR072477A1 (ru)
AU (1) AU2009268044A1 (ru)
BR (1) BRPI0915455A2 (ru)
CA (1) CA2730008A1 (ru)
CO (1) CO6331424A2 (ru)
DO (1) DOP2011000011A (ru)
EA (1) EA201170182A1 (ru)
EC (1) ECSP10010701A (ru)
IL (1) IL210001A0 (ru)
MX (1) MX2011000349A (ru)
NZ (1) NZ589904A (ru)
PE (1) PE20110412A1 (ru)
TW (1) TW201006826A (ru)
UA (1) UA100434C2 (ru)
WO (1) WO2010003996A1 (ru)
ZA (1) ZA201100223B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5910311B2 (ja) * 2012-05-23 2016-04-27 ニプロ株式会社 医薬錠剤およびその製造方法
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0955294B1 (en) * 1989-06-14 2003-09-24 Smithkline Beecham Corporation Imidazolyl-alkenoic acid
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
IL136142A0 (en) * 1997-11-17 2001-05-20 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
JP4575594B2 (ja) * 1998-07-20 2010-11-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 経口用固体剤形のエプロサルタン配合の生体内強化性処方
CA2547657A1 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
EP1734953A4 (en) * 2004-03-02 2008-08-20 Abeille Pharmaceuticals Inc CO-PR PARATIONS OF KITS OF BIOACTIVE AGENTS
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
US20070116762A1 (en) * 2005-11-07 2007-05-24 Wilson Edward S Compositions of stabilized ramipril in combination with another active agent

Also Published As

Publication number Publication date
WO2010003996A1 (en) 2010-01-14
CN102088961A (zh) 2011-06-08
AU2009268044A1 (en) 2010-01-14
MX2011000349A (es) 2011-02-22
EP2317987A1 (en) 2011-05-11
US20120302555A1 (en) 2012-11-29
UA100434C2 (en) 2012-12-25
JP2011527314A (ja) 2011-10-27
PE20110412A1 (es) 2011-07-04
KR20110031226A (ko) 2011-03-24
CO6331424A2 (es) 2011-10-20
TW201006826A (en) 2010-02-16
US20100010062A1 (en) 2010-01-14
DOP2011000011A (es) 2011-01-31
ECSP10010701A (es) 2011-01-31
BRPI0915455A2 (pt) 2017-06-27
NZ589904A (en) 2012-08-31
ZA201100223B (en) 2011-10-26
IL210001A0 (en) 2011-02-28
AR072477A1 (es) 2010-09-01
CA2730008A1 (en) 2010-01-14
EP2317987B1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
EA201690033A3 (ru) Морфинановые соединения
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
EA201290919A1 (ru) Индазольные соединения и их применение
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
PH12013500848A1 (en) Trpv1 antagonists and uses thereof
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
PH12017501294A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
EA201170040A1 (ru) Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и способы их получения и применения
DE602007012133D1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EA201270043A1 (ru) Замещенные производные изоиндолин-1,3-диона
EA200970512A1 (ru) Лечение по поводу множественной миеломы
WO2009000843A3 (fr) Traitement de l'insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l'aldostérone
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
EA201001094A1 (ru) Производные индазола
EA201070250A1 (ru) Противомикробный парентеральный состав
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
EA201170182A1 (ru) Композиции эпросартана
WO2010039742A3 (en) Methods to reduce b-helper t cells to treat autoimmune diseases
EA200500045A1 (ru) Новые соединения, их применение и получение
WO2010005585A3 (en) 4-aminoquinazoline prodrugs